A wealth of new drug targets has been discovered in recent years, and many more to come still lie buried in the immense data generated by the human genome project, and modern proteomics.
While pharmaceutical companies race to develop ligands for such targets, evidence for the pathophysiological relevance of such targets for successful therapeutic interventions often remains speculative.
Well-designed animal experiments modelling the target disease state can demonstrate the validity of therapeutic principles, provide guidance for the human pharmacology programme, and also allow insight into the disease process itself. ABX-CRO designs and implements complex studies in collaboration with our global imaging partner institutions, individually selected according to scientific project requirements, institutional capacity, and sponsor preferences.
|Animal PET and MRI
Imaging studies with PET or MRI are of particular interest for drug developments in oncology and the neurosciences. Whether you require small animal imaging in tumor-bearing rodents, or CNS imaging in small or large non-human primates (marmosets, cynomoglus apes), ABX-CRO with its top class service partners provides you with a turn-key solution, ranging from radiopharmaceutical services (e.g custom labelling of drug candidates), through advanced experimental or surgical interventions, performed by specially trained veterinarians, up to quantitative data analysis, using standard or special solutions, optimised around the study purposes. If human metabolism is to be modelled, mini-pig imaging may be an attractive alternative to primate imaging.
According to sponsor and project requirements, we offer PET projects in collaboration with leading institutions in Europe, North America and Japan.